Search

Displaying results 5151 - 5160 of 7452 in total
  1. Drug

    Peldesine

    go.drugbank.com/drugs/DB02568
    Investigational

    It has undergone phase I trials for the treatment of Human Immunodeficiency Virus (HIV) infections.

  2. Drug

    ISIS 325568

    go.drugbank.com/drugs/DB06099
    Investigational

    It was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping control type 2 diabetes.

  3. Drug

    Paliroden

    go.drugbank.com/drugs/DB05454
    Investigational

    It is indicated for use in Alzheimer's Disease and Parkinson’s.

  4. Drug

    Pipequaline

    go.drugbank.com/drugs/DB13991
    Experimental

    Pipequaline has a similar pharmacological profile to the reported for the benzodiazepines. … However, it presents a significant set of anxiolytic properties with a very little sedative, amnestic or anticonvulsant effect.

  5. Drug

    Lercanidipine

    go.drugbank.com/drugs/DB00528
    ApprovedInvestigationalWithdrawn

    Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.

  6. Drug

    Bilberry

    go.drugbank.com/drugs/DB14235
    ApprovedWithdrawn

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  7. Drug

    Acetoxolone

    go.drugbank.com/drugs/DB13640
    Experimental

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  8. Drug

    Oxamniquine

    go.drugbank.com/drugs/DB01096
    Approved

    An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female wor...

  9. Drug

    5-Methoxy-N,N-diisopropyltryptamine

    go.drugbank.com/drugs/DB01441
    ExperimentalIllicit

    This substance is abused for its hallucinogenic effects.

    Categories: Heterocyclic Compounds with 4 or More Rings
  10. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]